These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 18559761

  • 41. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
    Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS.
    J Clin Oncol; 2009 Oct 20; 27(30):5015-22. PubMed ID: 19738129
    [Abstract] [Full Text] [Related]

  • 42. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
    Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ.
    Oncologist; 2007 Jan 20; 12(1):72-8. PubMed ID: 17227902
    [Abstract] [Full Text] [Related]

  • 43. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
    Rose PG, Blessing JA, Lele S, Abulafia O.
    Gynecol Oncol; 2006 Aug 20; 102(2):210-3. PubMed ID: 16478630
    [Abstract] [Full Text] [Related]

  • 44. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides.
    Demierre MF, Vachon L, Ho V, Sutton L, Cato A, Leyland-Jones B.
    Arch Dermatol; 2003 May 20; 139(5):624-8. PubMed ID: 12756099
    [Abstract] [Full Text] [Related]

  • 45. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
    Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL.
    Arch Dermatol; 1987 Feb 20; 123(2):201-4. PubMed ID: 2949706
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
    Gerami P, Wickless SC, Rosen S, Kuzel TM, Ciurea A, Havey J, Guitart J.
    J Am Acad Dermatol; 2008 Aug 20; 59(2):245-54. PubMed ID: 18486274
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
    Grenader T, Goldberg A, Gabizon A.
    Anticancer Drugs; 2010 Oct 20; 21(9):868-71. PubMed ID: 20679886
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K.
    Jpn J Clin Oncol; 2008 Nov 20; 38(11):777-85. PubMed ID: 18927230
    [Abstract] [Full Text] [Related]

  • 54. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.
    Wollina U, Graefe T, Karte K.
    J Am Acad Dermatol; 2000 Jan 20; 42(1 Pt 1):40-6. PubMed ID: 10607318
    [Abstract] [Full Text] [Related]

  • 55. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
    Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G.
    Am J Clin Oncol; 2008 Aug 20; 31(4):369-74. PubMed ID: 18845996
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
    Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ.
    Gynecol Oncol; 2007 Aug 20; 106(2):375-80. PubMed ID: 17512575
    [Abstract] [Full Text] [Related]

  • 60. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study.
    Kamstrup MR, Lindahl LM, Gniadecki R, Iversen L, Skov L, Petersen PM, Loft A, Specht L.
    Br J Dermatol; 2012 Feb 20; 166(2):399-404. PubMed ID: 21967035
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.